Effortless expansion: an interview with Jenny Stjernberg
In this interview, Jenny Stjernberg sheds light on the multifaceted challenges facing the scale-up of cell therapies, exploring the importance of flexible manufacturing practices and why scaling down shouldn’t be overlooked. Jenny also explains how simplifying production processes ties into industry-wide standardization and what it takes to accelerate the journey of cell therapies from bench to bedside.
Meet the speaker
Jenny Stjernberg, Commercial Director, EMEA at ScaleReady (MN, USA)
Jenny Stjernberg leads Commercial Operations as EMEA Director for ScaleReady as part of the Global Leadership Team. In her role, she collaborates closely with the US Commercial Team and, together, they set the tone globally, enabling ScaleReady to challenge the way cell and gene therapy programs operate to adopt a simpler and consistent solution that centers around platform, process, and therefore, product continuity.
Prior to joining ScaleReady, Jenny spent five years successfully managing large sales and marketing teams within several cell and gene therapy companies. This, combined with her first-hand experience as a scientist and clinical account manager, has enabled her to gain a unique global perspective that spans the needs for academic research process development and commercial manufacturing operations.
Jenny’s career-long background in science began by obtaining her Master’s Degree in Medical Biology from Linköping University in Sweden, alongside a PhD in Medical Science, studying how cell-cell interactions in the bone marrow support the hematopoietic progenitors in their lineage decision.
